Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti‐RhD antibody with an optimized Fc for improved engagement of FCγRIII, in healthy volunteers

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Vox Sanguinis

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1423-0410.2012.01603.xPMID 22568808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use

  2011cited by this paper
• Towards 100% voluntary blood donation: a global framework for action.

  2010cited by this paper
• Impact of Glycosylation on Effector Functions of Therapeutic IgG †

  2010cited by this paper
• Effect of Producer Cell Line on Functional Activity of Anti-D Monoclonal Antibodies Destined for Prevention of Rhesus Sensitization

  2009cited by this paper
• Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16

  2008cited by this paper
• A human anti‐D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti‐D antibodies

  2008cited by this paper
• Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti‐D immunoglobulin: more questions than answers

  2007cited by this paper
• Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials.

  2006cited by this paper
• Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK.

  2005cited by this paper
• Pharmacokinetics and safety of recombinant anti‐RhD in healthy RhD‐negative male volunteers

  2004cited by this paper
• A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.

  2004cited by this paper
• Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

  2004cited by this paper
• A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative.

  2003cited by this paper
• Competitive enzyme‐linked immunoassay of monoclonal immunoglobulin G anti‐D preparations

  2003cited by this paper
• Pharmacokinetics of anti‐D IgG in pregnant RhD‐negative women

  2003cited by this paper
• In vivo studies of monoclonal anti-D and the mechanism of immune suppression.

  2002cited by this paper
• Section 1A: Rh serology. Coordinator's report.

  2002cited by this paper
• Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report

  2001cited by this paper
• RhD haemolytic disease of the fetus and the newborn.

  2000cited by this paper
• The Rh blood group system: a review.

  2000cited by this paper
• [Monoclonal anti-D immunoglobulin for prevention of hemolytic disease of the newborn].

  1994cited by this paper
• Results of Clinical Trials of RhoGAM * in Women

  1968cited by this paper
• Clearance of Rh-positive red cells by low concentrations of Rh antibody.

  1967cited by this paper
• Anaemia from bleeding of the fetus into the mother's circulation.

  1954cited by this paper
• ISOIMMUNIZATION IN PREGNANCY: ITS POSSIBLE BEARING ON THE ETIOLOGY OF ERYTHROBLASTOSIS FOETALIS

  1941cited by this paper

• Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) Modeling.

  2025cites this paper
• Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies [version 1; peer review: 2 approved]

  2022cites this paper
• Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

  2021cites this paper
• Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy

  2020cites this paper
• Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry

  2020cites this paper
• Haemolytic Disease of the Fetus and Newborn

  2020cites this paper
• Glycoengineering of Antibodies for Modulating Functions.

  2019cites this paper
• [EMABling®, a technology boosting the effector function of monoclonal antibodies: history and clinical applications twenty years after the discovery].

  2019cites this paper
• Red Blood Cell Alloimmunization in the Pregnant Patient.

  2018cites this paper
• Rhesus disease: a global prevention strategy.

  2018cites this paper
• The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells

  2017cites this paper
• Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

  2017cites this paper
• Practice Bulletin No. 181: Prevention of Rh D Alloimmunization.

  2017cites this paper
• Immune responses to red blood cell antigens

  2016cites this paper
• Antibodies to watch in 2017

  2016cites this paper
• Anti-human platelet antigen (HPA)-1a antibodies: For better or for worse

  2015cites this paper
• Prophylactic anti‐D preparations display variable decreases in Fc‐fucosylation of anti‐D

  2015cites this paper
• Clearance of Human IgG1-Sensitised Red Blood Cells In Vivo in Humans Relates to the In Vitro Properties of Antibodies from Alternative Cell Lines

  2014cites this paper
• Anti‐D prophylaxis: past, present and future

  2014cites this paper
• Multifactorial aspects of antibody-mediated blood cell destruction

  2014cites this paper
• Is an expression system for producing therapeutic antibodies with immunosuppressive properties found at last? Comment to letter by Dr. Quagliaroli

  2013cites this paper
• Quantitation of fetomaternal haemorrhage and F cells in unusual maternal blood samples by flow cytometry using anti‐D and anti‐HbF

  2013cites this paper
• Do YB2/0 cells produce alien sugars?

  2013cites this paper
• Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies

  2013cites this paper
• Prévention de l’allo-immunisation anti-D: des années 1970 à l’avènement des immunoglobulines monoclonales ?

  2013cites this paper
• Rozrolimupab, a mixture of recombinant human monoclonal anti‐D antibodies, for the treatment of primary immune thrombocytopenia – a review

  2013cites this paper